Training Program in Cancer Pharmacology

癌症药理学培训计划

基本信息

批准号：
7284809
负责人：
Ian Alexander Blair
金额：
$ 48.78万
依托单位：
UNIVERSITY OF PENNSYLVANIA
依托单位国家：
美国
项目类别：
财政年份：
2003
资助国家：
美国
起止时间：
2003-07-24 至 2009-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7284809
关键词：
1,2-diacylglycerol Academy Address Admission activity Adverse effects Adverse reactions Advisory Committees Affect Amelia American Angiogenesis Inhibitors Antineoplastic Agents Apoptosis Appendix Area Arginine Aromatic Hydrocarbons Aromatic Polycyclic Hydrocarbons Award B-Lymphocytes Back Binding Biochemical Biochemical Reaction Biochemistry Biochemistry and Pharmacology Cancer Activity Bioinformatics Biological Biological Markers Biological Models Biology Biomarkers and Prevention Research Branch Biometry Biophysics Boston Bypass CYP3A4 gene CYP3A5 gene Calcium Cancer Cell Growth Cancer Etiology Cancer Patient Carcinogens Cardiovascular system Caspase Catalytic RNA Cell Adhesion Cell Cycle Deregulation Cell Cycle Regulation Cell Death Cell Death Signaling Process Cell Proliferation Cell membrane Cells Cellular Structures Cellular biology Chemicals Chemistry Chemoprevention Chemotherapy-Oncologic Procedure Child Childhood Chimeric Proteins Class Clinical Clinical Pharmacology Clinical Research Clinical Trials Collaborations Commit Committee Members Communication Complement Complex Computational Biology Condition Consultations Coupling Crystallography Cyclic AMP-Dependent Protein Kinases Cyclin D1 Cyclin Regulation of Cell Cycle Pathway Cyclin-Dependent Kinases Cytoskeleton DNA Damage Data Databases Death Domain Depth Development Diglycerides Discipline Disease Doctor of Philosophy Dose Drug Delivery Systems Drug Kinetics Drug Receptors Drug effect disorder Drug resistance Drug usage Educational Curriculum Educational process of instructing Electronics Emerging Technologies Endocrine Endocytosis Endopeptidases Environment Environmental Carcinogens Enzymatic Biochemistry Enzyme Kinetics Enzymes Epidemiology Epipodophyllotoxin Compound Ethical Issues Ethics Eukaryota Eukaryotic Cell Evaluation Event Exhibits Exocytosis Expert Opinion Exposure to Faculty Family Focal Adhesion Kinase 1 Foundations Funding Future GTP-Binding Proteins GYPA gene Gene Expression Genetic Genetic Polymorphism Genetic Screening Genetic screening method Genomics Genotype Glutathione S-Transferase Glycophorin A Goals Grant Growth Guanosine Triphosphate Phosphohydrolases Health Heterocyclic Compounds Histone Acetylation Histone H2A Histone H3 Histones Home environment Hormonal Carcinogenesis Hormones Human Immunology Individual Individual Differences Integrins Interdisciplinary Study Investigation Ion Channel Protein Journals Kidney Kinetics Knowledge Laboratories Lead Leadership Learning Letters Life Ligand Binding Link Lipase Lipid Peroxides Lipids Literature Love Lung Neoplasms Malignant - descriptor Malignant Childhood Neoplasm Malignant Neoplasms Malignant neoplasm of prostate Marketing Marrow Measures Mediating Medical Medicine Membrane Mentors Messenger RNA Metabolism Methodology Methods Methotrexate Modeling Modems Modification Molecular Molecular Biology Molecular Epidemiology Molecular Epidemiology of Cancer Molecular Genetics Molecular Structure Molecular Target Monitor Monomeric GTP-Binding Proteins Mutation National Research Service Awards Neoplasm Metastasis Neuroblastoma Neurosciences Neurotransmitters New Agents Nifedipine Nuclear Receptors Numbers Occupational/Environmental Epidemiology Oncogenes Oral Oral Examination Oxidation-Reduction Oxidative Stress PO-1 Pain Paper Parasitology Pathway interactions Patients Pattern Pediatric Hospitals Pediatrics Pennsylvania Peptide Hydrolases Performance Personal Satisfaction Pharmaceutical Chemistry Pharmaceutical Preparations Pharmacodynamics Pharmacogenetics Pharmacology Phase Phase I Clinical Trials Philadelphia Phorbol Esters Phosphoric Monoester Hydrolases Phosphotransferases Physiological Physiology Play Population Post-Translational Protein Processing Postdoctoral Fellow Prevention Principal Investigator Process Production Program Development Promoter Regions Property Protein Biosynthesis Protein Isoforms Protein Kinase Protein Kinase C Protein-Serine-Threonine Kinases Proteins Proteome Proteomics Proto-Oncogene Proteins c-akt Publications Purpose Qualifying Quantitative Structure-Activity Relationship Quinones Radiation Range Rate Reaction Reactive Oxygen Species Reading Receptor Protein-Tyrosine Kinases Recommendation Recruitment Activity Regulation Research Research Ethics Research Personnel Research Project Grants Research Training Resistance Resources Response Elements Risk Role Rotation Running Safety Schedule Scheme Science Scientist Score Second Messenger Systems Sedation procedure Sensory Series Signal Pathway Signal Transduction Signal Transduction Pathway Site-Directed Mutagenesis Societies Staging Standards of Weights and Measures Stromal Neoplasm Structure Structure-Activity Relationship Students Supervision Surveys System TNFRSF10B gene TNFSF10 gene TP53 gene Techniques Technology Testing Text Therapeutic Therapeutic Agents Therapeutic Intervention Time Title Today Topoisomerase Toxic effect Training Training Programs Trans-Activators Transcriptional Activation Transition Elements Transmembrane Transport Tumor Promoters Tumor Suppressor Proteins Two-Dimensional Gel Electrophoresis United States National Institutes of Health Universities Urination Variant Water Week Work Writing angiogenesis base bench to bedside benzoquinone c-myc Genes cancer cell cancer epidemiology cancer genetics cancer pharmacology cancer prevention cancer proteomics cancer therapy carbonyl reductase (NADPH)carcinogenesis career cdc Genes chemical synthesis chemotherapeutic agent chemotherapy citrate carrier combinatorial chemistry concept cyclooxygenase 2 day design dosimetry driving force drug development drug discovery drug mechanism drug metabolism editorial enzyme mechanism experience falls frontier gastrointestinal gene therapy high throughput screening improved inhibitor/antagonist innovation instructor interdisciplinary approach interest lectures leukemia leukemogenesis mRNA Instability malignant breast neoplasm metabolomics metal complex multidisciplinary neuropsychiatry next generation novel novel therapeutics oxidation patient oriented research pharmacokinetic model phorbol ester receptor posters pre-doctoral programs prospective radioligand ranpirnase receptor receptor function response second messenger small molecule small molecule libraries structural biology success synthetic peptide therapeutic target trafficking tumor growth

项目摘要

DESCRIPTION (provided by applicant): Training Grant in Cancer Pharmacology. The purpose of the multidisciplinary Cancer Pharmacology training program is to provide predoctoral and postdoctoral students with a training environment that does not currently exist at the University of Pennsylvania. Drs. Blair (Program Director), Penning (Program Co-Director) and Assoian (Program Co-Director) have provided the sustained leadership required to develop a multidisciplinary program in molecular mechanisms of multi-stage carcinogenesis. There is now a real need for similar sustained leadership to be applied to the recruitment and training of both predoctoral and postdoctoral scientists in the multidisciplinary environment required for the field of cancer pharmacology. Major advances in the treatment of cancer patients in the next decade will result from multidisciplinary approaches in understanding of how malignant cells work at the molecular level and in designing novel therapeutic agents to disrupt these processes. Therefore, the proposed training program will help fill the current deficit of individuals qualified to develop the next generation of chemotherapeutic agents. The ultimate goal of the program is to provide training in cancer pharmacology that goes from laboratory to bedside and back again. Specifically, trainees will learn how cancer pharmacology can be used to identify new targets, how small molecules are synthesized and tested against these targets, how they are used in Phase I trials, how Phase I studies are developed into full clinical trials, and how epidemiology and pharmacogenetics are utilized to assess efficacy and lead to the discovery of new targets. Trainees will also receive specific training in how to project quantitative measures of drug effect from proof of concept in model systems into the rational selection of dosing in humans. These goals will be accomplished through the courses that are offered and the multidisciplinary research experiences that will be available from the faculty. The 26 faculty mentors with diverse complementary expertise are grouped into three programs: A. Pharmacology Discovery and Development. B. Cell and Molecular Cancer Pharmacology. C. Clinical Cancer Pharmacology. The trainees will have research mentors from two of these programs. The mentors on this proposed program have a very strong record of accomplishment as cancer researchers. They are Principal Investigators or Project Leaders on 68 NIH grants of which 39 (57%) are from NCI (27 RO-1s, 8 PO-1 Projects, 1 PO-1 Scientific Core, 1 P30 Scientific Core, 1 UO-1, 1 T-32). Apart from training grants, 11 of the mentors have NIH-funded (primarily through NCI) collaborative research grants. The mentors serve on Editorial Boards of 23 Journals and two of them are Journal Editors. Over the past 10-years, the mentors have trained 105 predoctoral students and 250 postdoctoral fellows; they currently have 52 predoctoral and 76 postdoctoral trainees in their laboratories. The mentors have clearly demonstrated that they have the scientific expertise and training experience to develop a new multidisciplinary training program in Cancer Pharmacology. Mentors have superb access to different patient populations through their association with 11 NCI-funded clinical programs. Furthermore, one of the mentors is Director of the General Clinical Research Center at the University of Pennsylvania (Dr. FitzGerald) and one is acting Director of the General Clinical Research Center at Children's Hospital of Philadelphia (Dr. Adamson). Both of these mentors have research programs with a focus on translational therapeutics and so they provide another outstanding training resource.

描述（由申请人提供）：癌症药理学的培训补助金。多学科癌症药理学培训计划的目的是为宾夕法尼亚大学目前不存在的培训环境提供培训环境。博士。布莱尔（计划总监），彭宁（计划联合指导）和阿索伊安（计划联合指导）提供了开发多阶段致癌分子机制多学科计划所需的持续领导。现在，在癌症药理学领域所需的多学科环境中，实际上需要将类似的持续领导应用于招募和培训。在未来十年中，癌症患者治疗的重大进展将是由于了解恶性细胞在分子水平上工作以及设计新型治疗剂以破坏这些过程的多学科方法。因此，拟议的培训计划将有助于填补有资格开发下一代化学治疗剂的个人的当前赤字。该计划的最终目标是提供从实验室到床边再返回的癌症药理学培训。具体而言，学员将学习如何使用癌症药理学来识别新靶标，如何对这些靶标进行合成和测试小分子，在I期试验中如何使用它们，如何将I期研究发展为完整的临床试验，以及如何利用流行病学和药物遗传学来评估效率和评估效率和发现新目标。学员还将接受特定的培训，以从模型系统中的概念验证验证到人类剂量的合理选择。这些目标将通过提供的课程以及教师提供的多学科研究经验来实现。具有多种互补专业知识的26位教师导师分为三个计划：A。药理学发现和开发。 B.细胞和分子癌药理学。 C.临床癌症药理学。学员将有来自其中两个计划的研究导师。作为癌症研究人员，该计划中的导师在成就方面具有很强的成就记录。他们是主要调查员或项目负责人 68个NIH赠款，其中39（57％）来自NCI（27 ro-1s，8个PO-1项目，1个PO-1科学核心，1 P30科学核心，1 UO-1，1 T-32）。除培训补助金外，有11位导师资助了NIH资助（主要是通过NCI）合作研究补助金。这些导师在23个期刊的编辑委员会上任职，其中两家是日记编辑。在过去的10年中，导师培训了105名专业学生和250名博士后研究员。他们目前在实验室中有52个占主导地位和76个博士后学员。这些导师清楚地表明，他们具有科学专业知识和培训经验，可以在癌症药理学领域开发新的多学科培训计划。通过与11个NCI资助的临床计划的联系，导师可以很好地访问不同的患者人群。此外，其中一位导师是宾夕法尼亚大学（Fitzgerald博士）的一般临床研究中心主任，也是费城儿童医院一般临床研究中心的代理总监（Adamson博士）。这两个导师都有研究计划，重点是转化治疗，因此他们提供了另一种出色的培训资源。